福安药业(300194.SZ)：子公司左氧氟沙星注射液获批上市

格隆汇5月9日丨福安药业(300194.SZ)公布，公司全资子公司福安药业集团烟台只楚药业有限公司(简称“只楚药业”)于近日收到国家药监局签发的关于左氧氟沙星注射液的药品注册证书。

左氧氟沙星注射液用于治疗成年人由敏感菌株所引起的下列感染：医院获得性肺炎、社区获得性肺炎、急性细菌性鼻窦炎、慢性支气管炎的急性细菌性发作、复杂性尿路感染等。

根据国家药监局相关信息平台显示：截止目前，左氧氟沙星注射液(含只楚药业)共有3家企业通过一致性评价或视同通过一致性评价。

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.